|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Cash Flows from Operating Activities | |||||
| Net income | |||||
| Net Income | |||||
| Adjustments to reconcile net income to net cash provided by operating activities: | |||||
| Depreciation and amortization | |||||
| Amortization of intangibles | |||||
| Amortization of securities | |||||
| Proceeds from loans held for sale | |||||
| Gain on sale of loans held for sale | |||||
| Provision for credit losses | |||||
| Deferred tax (benefit) expense | |||||
| Decrease (increase) in interest receivable | |||||
| (Decrease) increase in other assets | |||||
| (Decrease) in other assets | |||||
| Loans held for sale originated | |||||
| Provision for credit losses | |||||
| Deferred tax benefit | |||||
| (Increase) decrease in interest receivable | |||||
| Increase (decrease) in other assets | |||||
| Increase in accrued liabilities | |||||
| Loss on sale of investment securities | |||||
| Amortization of limited partnership investments | |||||
| Amortization of debt issuance costs | |||||
| Gain on sale of fixed assets, net | |||||
| Loss on sale and valuation adjustments of other real estate owned | |||||
| Purchase of other real estate owned | |||||
| Gain on sale of assets held for sale | |||||
| Gain on sale of OREO, net | |||||
| Gain on sale of limited partnership investment | |||||
| Income from life insurance investment | |||||
| Gain on life insurance investment | |||||
| Stock-based compensation expense | |||||
| Net Cash Provided by Operating Activities | |||||
| Cash Flows from Investing Activities | |||||
| Proceeds from maturities of securities available for sale | |||||
| Proceeds from paydowns of mortgage-backed securities | |||||
| Purchases of securities available for sale and other investments | |||||
| Changes in restricted stock, net | |||||
| Proceeds from sale of limited partnership investments | |||||
| Proceeds from maturity of investments available for sale | |||||
| Proceeds from paydowns of investments available for sale | |||||
| Purchases of investments available for sale | |||||
| Investment in restricted stock, net | |||||
| Investment in limited partnership investment | |||||
| Net increase in loans held for investment | |||||
| Net purchase of property and equipment | |||||
| Proceeds from life insurance benefits | |||||
| Proceeds from sale of other real estate owned | |||||
| Proceeds from the sale of fixed assets | |||||
| Net Cash (Used in) Provided by Investing Activities | |||||
| Cash Flows from Financing Activities | |||||
| Net change in deposits | |||||
| Net change in short-term debt | |||||
| Issuance of subordinated notes | |||||
| Redemption of subordinated notes | |||||
| Dividends paid in cash | |||||
| Proceeds from sale of common stock | |||||
| Repayments of long-term debt | |||||
| Proceeds from issuance of common stock | |||||
| Purchases of common stock | |||||
| Net Cash Provided by (Used in) Financing Activities | |||||
| Net Increase in Cash and Cash Equivalents | |||||
| Cash and Cash Equivalents, Beginning of Year | |||||
| Cash and Cash Equivalents, End of Year | |||||
| Cash paid for: | |||||
| Interest | |||||
| Income taxes | |||||
| Income taxes | |||||
| Supplemental non-cash disclosures: | |||||
| Change in unrealized loss on securities available for sale, net | |||||
| Cumulative effect of the adoption of ASC 326 | |||||
| Change in unrealized loss on securities available for sale, pretax | |||||
| Minimum pension asset adjustment, net | |||||
| Transfer Held to Maturity security from subsidiary to Bank available for sale portfolio | |||||
| Transfer from loans to other real estate owned | |||||
| Transfer from property and equipment to assets held for sale | |||||
Loading...